Golden logoGolden logo
Advanced Search
Kallyope

Kallyope

Kallyope is a New York City, New York based biotechnology company founded in 2015 developing therapeutics to improve human health by better understanding the gut-brain relationship.

Kallyope is a biotechnology and therapeutic microbiome company that was founded by Charles Zucker, Tom Maniatis, and Richard Axel in 2015 that is headquartered in New York City, New York. Kallyope uses gene sequencing, computational biology, neural imaging, cellular/molecular biology, and human genetics to understand the relationship between the human gut and the human brain in combination with their own drug discovery expertise to develop effective gut-brain therapies that improve human health and nutrition.

Funding
Series A

On December 10, 2015 Kallyope closed their series A funding round with $44 million in funding from The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Alexandria Venture investments, and Tony Evnin.

Series B

On February 22, 2018 Kallyope closed their series B funding round with $66 million in funding from Two Sigma Ventures, The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Euclidean Capital, and Alexandria Venture Investments.

Timeline

February 15, 2022
Kallyope raises a $236,000,000 series D round from Alexandria Venture Investments, Bill Gates, Casdin Capital, DNS Capital, Hartford Healthcare Endowment, Illumina Ventures, Lux Capital Management, Polaris Partners, StepStone Group, Tao Capital Partners and Two Sigma Ventures.
March 25, 2020
Kallyope raises a $112,000,000 series C round from The Column Group.
December 5, 2018
Kallyope raises a $21,000,000 series B round from Alexandria Venture Investments, Bill Gates, Illumina Ventures, Lux Capital Management, Polaris Partners and Two Sigma Ventures.
February 2018
Kallyope raises a $66,000,000 series B round from Euclidean Capital, Illumina Ventures, Lux Capital Management, Polaris Partners, The Column Group and Two Sigma Ventures.
December 10, 2015
Kallyope raises a $44,000,000 series A round from Alexandria Venture Investments, Anthony Evnin, Lux Capital Management, Polaris Partners and The Column Group.
2014
Kallyope was founded by Charles Zuker, Richard Axel and Tom Maniatis.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Kallyope and Novo Nordisk Team Up To Tackle Obesity | BioSpace

Mark Terry

Web

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
August 5, 2021
FierceBiotech
Kallyope has been relatively quiet since securing a $112 million raise in March 2020, but now the gut-brain biotech will have a former Merck leader at the helm to ramp up clinical work. Jay Galeota joins the New York City biotech as president and will become CEO by October 1.

References

Golden logo
By using this site, you agree to our Terms of Service.